Group 1 - The company, Heng Rui Pharmaceutical, announced a share buyback plan on September 11, 2025, involving an expenditure of RMB 15.927 million to repurchase 235,000 A-shares [1] - The repurchase price per share is set between RMB 67.20 and RMB 68.41 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年9月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括 ...

Core Viewpoint - The article discusses the significant decline in Chinese pharmaceutical stocks following reports of potential U.S. government restrictions on experimental drugs and clinical data from China, which could impact the growth of Chinese biotech firms in the U.S. market [2][3]. Group 1: Market Reaction - After the news, over 80% of innovative drug concept stocks in A-shares and around 50 stocks in the Hong Kong healthcare sector fell by more than 4% [2]. - Leading companies such as BeiGene and HengRui Medicine experienced stock price declines exceeding 4% in both A-shares and Hong Kong markets [2]. Group 2: U.S. Policy Implications - The U.S. government is reportedly considering an executive order to impose strict limits on experimental drugs and clinical data from China, which includes mandatory reviews of U.S. acquisitions of Chinese new drugs by the Committee on Foreign Investment in the United States (CFIUS) [2][3]. - The proposed measures aim to raise the FDA review thresholds for Chinese clinical trial data and encourage domestic drug production and procurement in the U.S. [2]. Group 3: Impact on Chinese Pharmaceutical Companies - If the rumored restrictions are implemented, it would negatively affect both Chinese and U.S. pharmaceutical sectors, as Chinese companies rely on expanding into larger markets like the U.S. [3][4]. - The current trend of multinational pharmaceutical companies acquiring innovative drug pipelines from China may be hindered, potentially reducing competition between U.S. and European firms [4]. Group 4: Future Outlook - Experts suggest that the potential U.S. policy changes could pose challenges for Chinese innovative drug companies aiming to enter the U.S. market, emphasizing the need for these companies to strengthen their domestic market presence [5]. - The article highlights that while the U.S. remains the largest pharmaceutical market, the increasing complexity of international regulations may lead to a reduced dependency of Chinese companies on the U.S. market over time [5].

Core Viewpoint - The article discusses the significant decline in Chinese pharmaceutical stocks due to potential U.S. government restrictions on experimental drugs and clinical data from China, which could impact the international expansion of Chinese innovative drugs [3][5]. Group 1: Market Reaction - Following reports of U.S. government plans to impose strict regulations, A-shares and Hong Kong stocks in the pharmaceutical sector saw a notable drop, with over 80% of innovative drug stocks in A-shares declining and around 50 stocks in Hong Kong dropping more than 4% [3]. - Leading companies such as BeiGene and Hengrui Medicine experienced stock price declines exceeding 4% in both A-shares and Hong Kong markets [3]. Group 2: Global Pharmaceutical Transactions - In the first half of 2025, global pharmaceutical transactions reached 456, a 32% year-on-year increase, with total upfront payments soaring to $11.8 billion, up 136% [4]. - The total transaction value hit $130.4 billion, reflecting a 58% year-on-year growth, with Chinese companies contributing nearly 50% of the total value and over 30% of the transaction volume [4]. Group 3: Implications of U.S. Regulations - If the rumored U.S. regulations are implemented, it would negatively affect both Chinese and U.S. pharmaceutical sectors, as Chinese companies rely on expanding into larger markets while U.S. firms may face increased costs and slower drug development [5][6]. - The potential restrictions could hinder U.S. pharmaceutical companies' access to lower-cost innovative drug pipelines from China, leading to competitive disadvantages against European firms [6]. Group 4: Future Challenges and Opportunities - The article highlights that the path for Chinese innovative drugs to penetrate the U.S. market is becoming increasingly challenging, necessitating a focus on expanding the domestic market [7]. - Despite the challenges posed by potential U.S. regulations, the long-term trend suggests that Chinese pharmaceutical companies may reduce their dependency on the U.S. market due to domestic policy reforms and the release of potential demand [8].

Group 1 - The core viewpoint of the news is that the stock prices of major Chinese pharmaceutical companies, including BeiGene and HengRui Medicine, have significantly dropped due to reports of potential U.S. government restrictions on experimental drugs and clinical data from China [2][4]. - As of September 11, 2023, over 80% of innovative drug concept stocks in A-shares and around 50 stocks in the Hong Kong healthcare sector experienced declines exceeding 4% [2]. - The U.S. government's proposed measures include mandatory reviews of U.S. acquisitions of Chinese new drugs by the Committee on Foreign Investment in the United States (CFIUS) and raising the FDA review thresholds for Chinese clinical trial data [2][4]. Group 2 - According to data from Yao Medicine, the global pharmaceutical transaction volume is expected to reach 456 deals in the first half of 2025, a year-on-year increase of 32%, with total upfront payments soaring by 136% to $11.8 billion and total transaction value hitting $130.4 billion, up 58% year-on-year [3]. - Chinese companies contributed nearly 50% of the total transaction value and over 30% of the transaction volume in global innovative drugs, indicating a growing recognition of the value of Chinese enterprises in the global market [3]. - The potential U.S. restrictions could negatively impact both Chinese and U.S. pharmaceutical sectors, as Chinese companies seek to expand their market presence while U.S. firms may face increased costs and delays in bringing new therapies to market [4][5]. Group 3 - The current trend of multinational pharmaceutical companies, including those from Europe, acquiring innovative drug pipelines from China is driven by the need to replenish their pipelines amid patent cliffs [5]. - The proposed U.S. measures are seen as part of a broader pattern of restrictions on the Chinese pharmaceutical industry, which includes previous actions by the U.S. government to increase tariffs and promote domestic drug production [5][6]. - Despite the potential negative impact of the proposed U.S. policy, experts believe that the immediate effect on the market is limited, as the policy is still in early discussion stages and involves complex negotiations among various stakeholders [6][7]. Group 4 - The news serves as a warning for Chinese innovative drug companies, indicating that capturing the U.S. market will become increasingly challenging [6]. - It emphasizes the importance for Chinese pharmaceutical companies to continue developing the domestic market, as there remains a significant gap between China's pharmaceutical market and that of the U.S. [6][7]. - The long-term trend suggests that as domestic healthcare reforms progress and demand is released, Chinese companies may reduce their reliance on the U.S. market for growth [7].

Group 1 - The Hong Kong pharmaceutical sector experienced a significant decline, with major stocks dropping sharply [1] - Gilead Sciences-B (01672.HK) fell nearly 15%, indicating a substantial loss in market value [1] - China Biopharmaceutical (01177.HK) saw a decline of over 10%, reflecting broader market trends affecting the industry [1] Group 2 - Other notable declines included CSPC Pharmaceutical Group (01093.HK), BeiGene (06160.HK), Hengrui Medicine (01276.HK), and WuXi AppTec (02359.HK), all of which experienced significant drops [1]

Core Insights - The article highlights the top and bottom AH premium rates for various stocks, indicating significant disparities in market valuations between H-shares and A-shares [1][2][3] Group 1: Top AH Premium Rates - Northeast Electric (00042) leads with an AH premium rate of 800.00%, followed by Hongye Futures (03678) at 227.63% and Andeli Juice (02218) at 219.28% [1][2] - Other notable mentions include Fudan Zhangjiang (01349) with a premium of 215.70% and Beijing Mechanical & Electrical (00187) at 214.38% [2] Group 2: Bottom AH Premium Rates - CATL (03750) has the lowest AH premium rate at -10.67%, followed by Hengrui Medicine (01276) at -1.72% and Zijin Mining (02899) at 4.00% [1][2] - Additional companies with low premium rates include China Merchants Bank (03968) at 5.29% and Midea Group (00300) at 6.40% [2] Group 3: Top Deviation Values - Zhaoyan New Drug (06127) shows the highest deviation value at 25.76%, followed by Ganfeng Lithium (01772) at 19.31% and Kaisheng New Energy (01108) at 18.78% [1][2] - Other companies with significant deviation values include Dongjiang Environmental (00895) at 16.43% and Tianqi Lithium (09696) at 16.34% [2] Group 4: Bottom Deviation Values - Fosun Pharma (02196) has the lowest deviation value at -21.97%, followed by Longyuan Power (00916) at -20.23% and Longpan Technology (02465) at -17.81% [1][3] - Additional companies with low deviation values include BYD Company (01211) at -15.75% and Jiangxi Copper (00358) at -15.61% [3]

江蘇恒瑞醫藥股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年9月9日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司成都盛迪医 药有限 ...

Core Viewpoint - The article discusses the surge in A-share companies listing in Hong Kong through the A+H model, highlighting the significant increase in fundraising and the emergence of new listing methods, which reflect the growing interconnection between mainland and Hong Kong markets [3][4][5]. Group 1: A+H Listing Surge - In the first eight months of this year, Hong Kong Stock Exchange (HKEX) raised a total of HKD 134.5 billion in new stock financing, a nearly sixfold increase year-on-year [3]. - A+H listings accounted for 70% of the total fundraising in the first half of the year, indicating strong participation from A-share companies [3][4]. - Eleven A-share companies have successfully completed A+H listings this year, raising over HKD 90 billion, which represents about 70% of the total IPO fundraising in Hong Kong [4]. Group 2: New Listing Methods - New methods for A+H listings have emerged, such as share swap mergers and privatization, which provide companies with alternative financing channels [5]. - Zhejiang Hu-Hang-Zhou announced a share swap merger with Zhenyang Development to achieve A+H listing, while New Hope Group plans to privatize New Hope Energy through its wholly-owned subsidiary [5]. Group 3: Market Structure Improvement - The trend of A+H listings is expected to improve the industry structure of the Hong Kong market, attracting more capital and updating the composition of A+H listed companies [6]. - The recent strong performance of the Hong Kong stock market and the influx of southbound capital have led to a significant decrease in A+H premium, with some companies trading at a discount in A-shares compared to H-shares [6]. Group 4: A+H Premium Situation - As of September 5, among 161 A+H stocks, five had H-share prices exceeding A-share prices, with CATL showing the largest discount at -17.43% [7]. - The article notes that the A+H premium is expected to continue declining, influenced by the low interest rate environment in mainland China [7].

Group 1 - The Hong Kong Stock Exchange (HKEX) has seen a significant increase in new stock financing, reaching HKD 134.5 billion in the first eight months of the year, a nearly sixfold year-on-year growth, with A+H listings accounting for 70% of the total fundraising in the first half of the year [1][2] - A total of 11 A-share companies have completed A+H listings this year, raising over HKD 90 billion, which represents about 70% of the total IPO fundraising in the Hong Kong market [2] - More than 51 A-share companies are currently in the process of preparing for their listings in Hong Kong, including notable firms like SANY Heavy Industry and Sungrow Power Supply [2][3] Group 2 - Innovative listing methods are emerging in the current A+H expansion wave, such as share swap mergers and privatization, which provide companies with new financing channels and resource optimization opportunities [3] - Zhejiang Hu-Hang-Yong plans to achieve A+H listing through a share swap merger with Zhenyang Development, while New Hope Group intends to privatize New Hope Energy through its wholly-owned subsidiary and list on the Hong Kong Stock Exchange [3] Group 3 - The enthusiasm for A+H listings is driven by multiple factors, including support from mainland authorities for quality companies to list in Hong Kong and the ongoing optimization of the approval process by HKEX [4] - The trend of A+H listings is expected to improve the industry structure of the Hong Kong market, attracting more capital and updating the composition of A+H listed companies [5] Group 4 - As of September 5, 2023, among 161 A+H stocks, only 5 have H-share prices exceeding A-share prices, with CATL showing the largest discount at 17.43% [5][6] - The premium of A-shares over H-shares has significantly decreased, reflecting a shift in market sentiment and a revaluation of H-shares due to the low interest rate environment in mainland China [6]